| |
| |
|
| Insider
Information: |
Stahl Neil |
| Relationship: |
EVP Research and Devel... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
50,999 |
|
|
Indirect Shares
|
10,439 |
|
|
| Direct
Value |
$50,235,035 |
|
|
|
Indirect Value
|
$10,282,624 |
|
|
| Total
Shares |
61,438 |
|
|
| Total
Value |
$60,517,659 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
4
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 57.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Regeneron Pharmaceuticals Inc |
REGN |
EVP Research and Devel... |
2024-02-26 |
50,999 |
2024-02-26 |
10,439 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| REGN |
Regeneron Pharmaceuticals... |
SVP, PreclinDevel & Biomol Sci |
• – – |
2005-08-05 |
4 |
S |
$9.42 |
$101,098 |
D/D |
(10,677) |
5,371 |
|
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Research & Devel Sciences |
• – – |
2008-09-30 |
4 |
S |
$21.50 |
$223,119 |
D/D |
(10,317) |
350 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2012-02-14 |
4 |
S |
$107.83 |
$3,436,651 |
D/D |
(31,202) |
80,203 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2012-02-15 |
4 |
S |
$107.79 |
$2,273,036 |
D/D |
(21,082) |
59,121 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2012-08-29 |
4 |
S |
$144.92 |
$2,460,647 |
D/D |
(16,884) |
59,121 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Devel Sciences |
• – – |
2012-11-21 |
4 |
S |
$173.80 |
$4,245,442 |
D/D |
(24,357) |
59,121 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Devel Sciences |
• – – |
2012-11-30 |
4 |
S |
$181.01 |
$3,110,114 |
D/D |
(17,182) |
41,939 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2013-05-13 |
4 |
S |
$276.71 |
$6,378,806 |
D/D |
(23,038) |
48,988 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-02-13 |
4 |
S |
$316.55 |
$7,209,136 |
D/D |
(22,612) |
24,391 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-08-07 |
4 |
S |
$340.39 |
$252,304 |
D/D |
(741) |
27,273 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-08-08 |
4 |
S |
$340.60 |
$715,340 |
D/D |
(2,100) |
25,173 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-08-11 |
4 |
S |
$339.33 |
$3,959,204 |
D/D |
(11,646) |
13,527 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-11-21 |
4 |
S |
$415.16 |
$1,289,902 |
D/D |
(3,107) |
5,477 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-11-24 |
4 |
S |
$409.71 |
$901,523 |
D/D |
(2,200) |
3,277 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2015-11-06 |
4 |
S |
$562.37 |
$11,260,068 |
D/D |
(20,000) |
44,130 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2015-11-09 |
4 |
S |
$558.37 |
$12,377,559 |
D/D |
(22,101) |
22,029 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2018-05-24 |
4 |
S |
$295.09 |
$3,366,092 |
D/D |
(11,407) |
31,973 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2019-11-08 |
4 |
S |
$330.56 |
$2,492,888 |
D/D |
(7,364) |
22,455 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2019-11-26 |
4 |
S |
$363.58 |
$1,458,467 |
D/D |
(4,006) |
22,455 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-05-11 |
4 |
S |
$567.50 |
$3,021,289 |
D/D |
(5,305) |
11,380 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-05-17 |
4 |
S |
$518.63 |
$9,101,460 |
D/D |
(17,521) |
24,280 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2022-08-05 |
4 |
S |
$606.78 |
$14,569,134 |
D/D |
(23,782) |
52,795 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2023-08-22 |
4 |
S |
$840.53 |
$9,810,082 |
D/D |
(11,665) |
53,100 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2024-02-07 |
4 |
S |
$947.34 |
$7,637,954 |
D/D |
(8,037) |
52,019 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
officerTitle |
• – – |
2006-02-03 |
4 |
OE |
$7.41 |
$296,400 |
D/D |
40,000 |
27,127 |
|
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
